<DOC>
	<DOCNO>NCT02034123</DOCNO>
	<brief_summary>GSK2879552 potent , selective , mechanism-based inactivator Lysine Specific Demethylase 1 ( LSD1 ) / CoRepressor Element-1-Silencing Transcription factor ( CoREST ) activity . This phase I , open-label , multi-center , non-randomized , 2-part first time human ( FTIH ) study GSK2879552 . Part 1 dose escalation phase determine recommend phase 2 dose ( RP2D ) GSK2879552 base safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) profile observed oral administration GSK2879552 . Any dose level ( ) may expand 12 subject order collect additional data PK PD.The safety PK/PD data review prior dose decision , dose escalation guide Neuenschwander -continuous reassessment method ( N-CRM ) . Built-in safety constraint place prevent expose subject undue risk toxicity . Once RP2D identify , expansion cohort ( Part 2 ) 30 subject enrol evaluate clinical activity tolerability GSK2879552 subject relapsed/refractory SCLC .</brief_summary>
	<brief_title>Investigation GSK2879552 Subjects With Relapsed/Refractory Small Cell Lung Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Provided sign write informed consent Males females &gt; =18 year age ( time consent obtain ) . Histologically cytologically confirm diagnosis small cell lung carcinoma . Subjects must measurable disease per RECIST 1.1 ( Part 2 ) . Recurrent refractory disease receive least one prior standard/approved platinumcontaining chemotherapy regimen , standard therapy refuse . Part 2 : Subjects must recurrent disease receive maximum two prior chemotherapy regimen include least one platinum contain regimen . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; = 1 . ( ECOG performance status 0 1 ) . Tumor tissue requirement : Availability archival tissue , willingness undergo fresh biopsy baseline ; Enrollment PK/PD cohort may limited subject disease amenable pre postdose biopsy , willingness undergo biopsy . All prior treatmentrelated toxicity must National Cancer Institute Common Toxicity Criteria Adverse Events ( NCICTCAE ) , version 4.0 &lt; =Grade 1 time enrollment ( except alopecia ) Adequate baseline organ function Women childbearing potential must negative serum pregnancy test within 7 day first dose study treatment agree use effective contraception , define protocol , study 7 day follow last dose study treatment . Men female partner childbearing potential must either prior vasectomy agree use effective contraception describe protocol administration first dose study treatment 3 month last dose study treatment allow clearance alter sperm . Able swallow retain orally administer study treatment clinically significant gastrointestinal ( GI ) abnormality may alter absorption malabsorption syndrome major resection stomach and/or bowel . French subject : In France , subject eligible inclusion study either affiliate beneficiary social security category . Concurrent malignancy SCLC . History malignancy allow long evidence active disease need treatment . Currently receive anticancer therapy . Exceptions : Zoledronic acid denosumab treat bone metastasis allow . Prior treatment temozolomide , dacarbazine procarbazine . Prior treatment poly ADP ribose polymerase ( PARP ) inhibitor ( e.g. , olaparib , ABT888 ) . Baseline Montreal Cognitive Assessment ( MOCA ) score 22 low . Received major surgery , radiotherapy , immunotherapy within 4 week GSK2879552 administration . Chemotherapy regimens delay toxicity within last four week ( six week prior nitrosourea mitomycin C ) . Chemotherapy regimens give continuously weekly basis limit potential delayed toxicity palliative radiation limit area within last two week . Administration investigational drug within 28 day 5 halflives , whichever short precede first dose study treatment ( ) study . French subject : The French subject participate study use investigational study treatment ( ) previous 28 day . Subjects current/a history bleed disorder coagulopathy particularly high risk bleed complication . Requiring anticoagulant therapeutic dos platelet inhibitor . Current use prohibit medication expect require medication treatment investigational drug Evidence severe uncontrolled systemic disease . Any serious and/or unstable preexist medical , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure , opinion investigator Known active Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) Hepatitis C Virus ( HCV ) infection . Subjects laboratory evidence HBV clearance may enrol Leptomeningeal metastasis spinal cord compression due disease . Subjects previously untreated uncontrolled brain metastasis . Cardiac abnormality Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate GSK2879552 LSD1 inhibitor contraindicate participation . Lactating female Consumption Seville orange , grapefruit , grapefruit hybrid , grapefruit juice , pommelos , exotic citrus fruit , 1 day prior first dose study treatment ( ) last dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>First time human</keyword>
	<keyword>Small cell lung carcinoma</keyword>
	<keyword>Oncology</keyword>
	<keyword>GSK2879552</keyword>
	<keyword>LSD1 inhibitor</keyword>
</DOC>